

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Application Number

10/666,511

Filing Date

September 17, 2003

First Named Inventor

RADEMACHER, Thomas

Group Art Unit

Unassigned

Examiner Name

Unassigned

Total Number of Pages in This Submission

8

Attorney Docket Number

1012E-910001US

**ENCLOSURES (check all that apply)**☐

Fee Transmittal Form

☐

Fee Attached

☐

Amendment / Response

☐

After Final

☐

Affidavits/declaration(s)

☐

Extension of Time Request

☐

Express Abandonment Request

☒

Information Disclosure Statement

☐

Certified Copy of Priority Document(s)

☐Response to Missing Parts/  
Incomplete Application☐Response to Missing  
Parts under 37 CFR  
1.52 or 1.53☐Assignment Papers  
(for an Application)☐

Drawing(s)

☐

Licensing-related Papers

☐Petition Routing Slip (PTO/SB/69)  
and Accompanying Petition☐Petition to Convert to a  
Provisional Application☐Power of Attorney, Revocation  
Change of Correspondence  
Address☐

Terminal Disclaimer

☐

Small Entity Statement

☐

Request for Refund

☐After Allowance Communication  
to Group☐Appeal Communication to Board  
of Appeals and Interferences☐Appeal Communication to Group  
(Appeal Notice, Brief, Reply Brief)☐

Proprietary Information

☐

Status Letter

☒Additional Enclosure(s)  
(please identify below):receipt acknowledgment  
postcard**Authorization to Charge Deposit Account**

Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.

Remarks

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**Firm  
or  
Individual name

Emily M. Haliday, Reg. No. 38,903, Quine Intellectual Property Law Group, P.C.

Signature

Date

Feb. 11, 2004

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.


Typed or printed name

Tracie Brooks

Signature

Date

2-11-04



I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450, on 2-11-04

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

By Tracie Brooks  
Tracie Brooks

Attorney Docket No. 1012E-910001US  
Client Ref. No. SJK/BP6174346

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

RADEMACHER, Thomas William, et al.

Application No.: 10/666,511

Filed: September 17, 2003

For: MATERIALS AND METHODS  
RELATING TO THE DIAGNOSIS  
AND TREATMENT OF DIABETES  
AND OBESITY

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR § 1.97 and  
§ 1.98

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The references cited on the attached PTO-1449 forms are being called to the attention of the Examiner to make of record references cited in parent application USSN 09/254,800 filed June 11, 1999. Pursuant to 37 CFR § 1.98(d), copies of references cited in parent application USSN 09/254,800 filed June 11, 1999 are not provided. However the applicants will gladly provide fresh copies of any references requested by the Examiner.

It is respectfully requested that the cited information on the attached 1449 form(s) be expressly considered during the prosecution of this application, and that references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

RADEMACHER, Thomas William, et al.


Application No.: 10/666,511

Page 2

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

  
Emily M. Haliday, J.D., Ph.D.  
Reg. No. 38,903

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.  
P.O. BOX 458  
Alameda, CA 94501  
(510) 337-7871  
Fax (510) 337-7877

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

Complete if Known

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/666,511
Filing Date	September 17, 2003
First Named Inventor	RADEMACHER, Thomas William
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	1012E-910001US
Date Submitted	February 11, 2004

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	1	The Merck Manual of Diagnosis and Therapy, 17 <sup>th</sup> Edition, Merck Research Laboratories, 1999, pages 165-171	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


# COPY FROM PARENT

Attorney Docket No.: ~~21828-0705~~ 1012E-910001US

FORM PTO-1449 (Modified)

## LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT(S)' INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



ATTY. DOCKET NO.

~~21828-0705~~  
1012E-910001US

SERIAL NO.

~~09/254,800~~

10/666,511

APPLICANT *Rodaris Pharmaceuticals Limited*  
~~Rademacher Group Limited~~

FILING DATE

June 11, 1999

GROUP ART UNIT

1641

### REFERENCE DESIGNATION

### U.S. PATENT DOCUMENTS

EXAM'R INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	Subclass	Filing Date if Appropriate
	A1 ***	5,122,603	06/16/92	Larner et al.	536	18.7	
	A2	5,183,764	02/02/93	Kennington et al.	436	131	
	A3	5,427,956	06/27/95	Kennington et al.	436	131	
	A4	5,750,348	05/12/98	Larner	435	7.1	


### FOREIGN PATENT DOCUMENTS

EXAM'R INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	Subclass	TRANSLATN
	B1 ***	WO 96/29425	09/26/96	PCT			yes no
	B2 ***	0 532 915 A3	03/24/93	Europe			

### OTHER ART (Include Author, Title, Date, Pertinent Pages, etc.)

C1	Alberti K.G.M.M. and Press, C.M. "The Biochemistry of the Complications of Diabetes Mellitus," <u>Complications of Diabetes</u> Eds Keen, H. and Jarret, J. Publishers Edward Arnold Ltd., London, pp. 231-270 (1982).
C2	Asplin, I. et al., "chiro-inositol Deficiency and Insulin Resistance: A Comparison of the chiro-Inositol- and the myo-Inositol-Containing Insulin Mediators Isolated from Urine, Hemodialysate, and Muscle of Control and Type II Diabetic Subjects," 90 <i>Proc. Natl. Acad. Sci.</i> 5924-5928 (1993).
C3	Baron, A., "The Coupling of Glucose Metabolism and Perfusion in Human Skeletal Muscle. The Potential Role of Endothelium-Derived Nitric Oxide," 45 (Suppl. 1) <i>Diabetes</i> S105-S109 (1996).
C4	Bennett, P. et al., "Epidemiology and Natural History of NIDDM: Non-obese and Obese." In: <u>International Textbook of Diabetes Mellitus</u> , Eds. Alberti, K. et al. John Wiley & Sons Ltd., pp.147-169 (1992).
C5	Brautigan, D., "Protein Phosphatases," 49 <i>Recent Prog. Hormone Res.</i> 197-214 (1994).
C6 ***	Caro, H.N. et al., "Isolation and partial characterisation of insulin-mimetic inositol phosphoglycans from human liver," 61 <i>Biochemical and Molecular Medicine</i> 214-228 (August 1997)
C7	Cohen, P., "The Structure and Regulation of Protein Phosphatases," 58 <i>Annu. Rev. Biochem.</i> 453-508 (1989).
C8	Craig, J. et al., "Chiroinositol Deficiency and Insulin Resistance," In: <u>Molecular Biology of Diabetes. Part II</u> , Eds. Draznin, B. and LeRoith, D., Humana Press Inc., Totowa, NJ, pp. 343-362 (1994).
C9	DeFronzo, R. et al., "Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus," 333(9) <i>The New England Journal of Medicine</i> 541-549 (1995).

OTHER ART (Include Author, Title, Date, Pertinent Pages, etc.) [continued]




C10	DeFronzo, R. et al., "Pathogenesis of NIDDM: A Balanced Overview," 15(3) <i>Diabetes Care</i> 318-368 (1992).
C11	DeFronzo, R., "The Triumvirate: $\beta$ -Cell, Muscle, Liver: A Collusion Responsible for NIDDM," 37 <i>Diabetes</i> 667-687 (1988).
C12	Farese, R. et al., "Insulin-Induced Activation of Glycerol-3-Phosphate Acyltransferase by <i>chiro</i> -Inositol-Containing Insulin Mediator is Defective in Adipocytes of Insulin Resistant, Type II Diabetic Goto-Kakizaki Rats," 91 <i>Proc. Natl. Acad. Sci.</i> 11040-11044 (1994).
C13	Ferrannini, E., "Physiological and Metabolic Consequences of Obesity," 44(9) (Suppl. 3) <i>Metabolism</i> 15-17 (1995).
C14	Fonteles, M.C. et al., "Infusion of pH 2.0 D- <i>chiro</i> inositol glycan insulin putative mediator normalizes plasma glucose in streptozotocin diabetic rats at a dose equivalent to insulin without inducing hypoglycaemia," <i>Diabetologia</i> 39:731-734 (1996).
C15	Himsworth, H., "Diabetes Mellitus: Its Differentiation Into Insulin-Sensitive and Insulin-Insensitive Types," <i>The Lancet</i> 127-130 (1936).
C16	Huang, L. et al., "Chiroinositol Deficiency and Insulin Resistance. III. Acute Glycogenic and Hypoglycemic Effects of Two Inositol Phosphoglycan Insulin Mediators in Normal and Streptozotocin-Diabetic Rats <i>in Vivo</i> ," 132(2) <i>Endocrinology</i> 652-657 (1993).
C17	Kennington, A. et al., "Low Urinary <i>chiro</i> -Inositol Excretion in Non-Insulin Dependent Diabetes Mellitus," 323(6) <i>The New England Journal of Medicine</i> 373-378 (1990).
C18	Krentz, A. and Nattress, M., "Insulin Resistance: A Multifaceted Metabolic Syndrome. Insights Gained Using a Low-Dose Insulin Infusion Technique," 13 <i>Diabetic Medicine</i> 30-39 (1996).
C19	Kubota, M. et al., "Portal Insulin Delivery is Superior to Peripheral Delivery in Handling of Portally Delivered Glucose," 45(2) <i>Metabolism</i> 150-154 (1996).
C20	Kunjara, S. et al., "Tissue Specific Release of Inositol Phosphoglycans," In: <i>Biopolymers and Bioproducts: Structure, Function, and Applications</i> , J. Svast et al. (ed), Dokya Publications, pp. 301-306 (1995).
C21	Larner, J. et al., "Insulin Mediators and the Control of Pyruvate Dehydrogenase Complex," 573 <i>Annals New York Academy of Sciences</i> 297-305 (1989).
C22	Larner, J. et al., "Insulin Mediators: Structure and Formation," 53 <i>Cold Spring Harbour Symposia on Quantitative Biology</i> 965-971 (1988).
C23	Lazar, D. et al., "Stimulation of Glycogen Synthesis by Insulin in Human Erythroleukemia Cells Requires the Synthesis of Glycosyl-Phosphatidylinositol," 91 <i>Proc. Natl. Acad. Sci.</i> 9665-9669 (1994).
C24	Lilley, K. et al., "Insulin Mediator Stimulation of Pyruvate Dehydrogenase Phosphatases," 296(1) <i>Archives of Biochemistry and Biophysics</i> 170-174 (1992).
C25	Machicao, F. et al., "Mannose, Glucosamine and Inositol Monophosphate Inhibit the Effects of Insulin on Lipogenesis. Further Evidence for a Role for Inositol Oligosaccharides in Insulin Action," 266 <i>Biochem. J.</i> 909-916 (1990).
C26	Martiny, L. et al., "Control by Thyotropin of the Production by Thyroid Cells of an Inositol Phosphate-Glycan," 2(1) <i>Cell Signalling</i> 21-27 (1990).
C27	Misek, D. and Saltiel, A., "An Inositol Phosphate Glycan Derived From a <i>Trypanosoma brucei</i> Glycosyl Phosphatidylinositol Promotes Protein Dephosphorylation in Rat-Epididymal Adipocytes," 135(5) <i>Endocrinology</i> 1869-1876 (1994).
C28	Moller, D. and Flier, J.S., "Insulin Resistance - Mechanisms, Syndromes, and Implications," 325(13) <i>The New England Journal of Medicine</i> 938-948 (1991).
C29	Moncada, S. and Higgs, A., "The L-Arginine-Nitric Oxide Pathway," 329(27) <i>The New England Journal of Medicine</i> 2002-2012 (1993).
C30	Muller, G. et al., "The Sulphonylurea Drug, Glimepiride, Stimulates Release of Glycosylphosphatidylinositol-Anchored Plasma-Membrane Proteins from 3T3 Adipocytes," 289 <i>Biochem. J.</i> 509-521 (1993).

COPY FROM PATENT

Attorney Docket No.: 21828-0705

Serial No. 10/666,511

## OTHER ART (Include Author, Title, Date, Pertinent Pages, etc.) [continued]




C31	Newman, J. et al., "Assay of Insulin Mediator Activity with Soluble Pyruvate Dehydrogenase Phosphatase," 116(5) <i>Endocrinology</i> 1912-1919 (1985).
C32	O'Rahilly, S. and Moller, D., "Mutant Insulin Receptors in Syndromes of Insulin Resistance," 36 <i>Clinical Endocrinology</i> 121-132 (1992).
C33	Ortmeyer, H. et al., "Chiroinositol Deficiency and Insulin Resistance. I. Urinary Excretion Rate of Chiroinositol is Directly Associated with Insulin Resistance in Spontaneously Diabetic Rhesus Monkeys," 132(2) <i>Endocrinology</i> 640-645 (1993).
C34	Ortmeyer, H. et al., "Chiroinositol Deficiency and Insulin Resistance. II. Acute Effects of D-Chiroinositol Administration in Streptozotocin-Diabetic Rats, Normal Rats Given a Glucose Load, and Spontaneously Insulin-Resistant Rhesus Monkeys," 132(2) <i>Endocrinology</i> 646-651 (1993).
C35 ***	Ortmeyer, H. et al., "In vivo D-chiroinositol activates skeletal muscle glycogen synthase and inactivates glycogen phosphorylase in rhesus monkeys," 6 <i>Journal of Nutritional Biochemistry</i> 499-503 (1995).
C36	Ostlund, R. et al., "D-chiro-Inositol Metabolism in Diabetes Mellitus," 90 <i>Proc. Natl. Acad. Sci.</i> 9988-9992 (1993).
C37	Panzram, G., "Mortality and Survival in Type 2 (Non-Insulin-Dependent) Diabetes Mellitus," 30 <i>Diabetologia</i> 123-131 (1987).
C38	Polonsky, K. et al., "Non-Insulin-Dependent Diabetes Mellitus - A Genetically Programmed Failure of the Beta Cell to Compensate for Insulin Resistance," 334(12) <i>Seminars in Medicine of the Beth Israel Hospital, Boston</i> 777-783 (1996).
C39	Prochazka, M. et al., "Molecular and Linkage Analysis of Type-1 Protein Phosphatase Catalytic Beta-Subunit Gene: Lack of Evidence for its Major Role in Insulin Resistance in Pima Indians," 38 <i>Diabetologia</i> 461-466 (1995).
C40	Rademacher, T. et al., "Inositolphosphoglycan Second Messengers," 27 <i>Brazilian J. Med. Biol.</i> 327-341 (1994).
C41	Reaven, G. et al., "Hypertension and Associated Metabolic Abnormalities - The Role of Insulin Resistance and the Sympathoadrenal System," 334(6) <i>The New England Journal of Medicine</i> 374-381 (1996).
C42	Reaven, G., "Banting Lecture 1998. Role of Insulin Resistance in Human Disease," 37 <i>Diabetes</i> 1595-1607 (1988).
C43	Reaven, G., "Pathophysiology of Insulin Resistance in Human Disease," 75(3) <i>Physiological Reviews</i> 473-486 (1995).
C44	Rodbell, M., "Metabolism of Isolated Fat Cells," 239(2) <i>The Journal of Biological Chemistry</i> 375-380 (1964).
C45	Romero, G. and Lerner, J., "Insulin Mediators and the Mechanism of Insulin Action," 24 <i>Advances in Pharmacology</i> 21-50 (1993).
C46	Romero, G. et al., "Anti-Inositolglycan Antibodies Selectively Block Some of the Actions of Insulin in Intact BC <sub>3</sub> H1 Cells," 87 <i>Proc. Natl. Acad. Sci.</i> 1476-1480 (1990).
C47	Romero, G. et al., "Phosphatidylinositol-Glycan Anchors of Membrane Proteins: Potential Precursors of Insulin Mediators," 240 <i>Science</i> 509-511 (1988).
C48	Romero, G., "Inositolglycans and Cellular Signaling," 15 <i>Cell Biology International Reports</i> 827-852 (1991).
C49 ***	Saltiel, A. et al., "The Role of Glycosylphosphoinositides in Signal Transduction," 45 <i>Recent Prog. Horm. Res.</i> 353-382 (1989).
C50	Sanchez-Arias, J. et al., "Impairment of Glycosyl-Phosphatidylinositol-Dependent Insulin Signaling System in Isolated Rat Hepatocytes by Streptozotocin-Induced Diabetes," 131(4) <i>Endocrinology</i> 1727-1733 (1992).
C51	Serrano, J. et al., "Insulin Resistance: Cellular and Molecular Mechanisms," In: <u>Recent Advances in Endocrinology and Metabolism</u> , Vol. 4, pp. 167-183 (1992).

COPY FROM PATENT

 1012E-910001US  
 Attorney Docket No.: ~~21828-0705~~  
 Serial No. 101666, 511

## OTHER ART (Include Author, Title, Date, Pertinent Pages, etc.) [continued]



C52	Sochor, M. et al., "Glucose Over- and Underutilization in Diabetes: Comparative Studies of the Change in Activities of Enzymes of Glucose Metabolism in Rat Kidney and Liver," 7 <i>Molecular Physiology</i> 51-67 (1985).
C53	Stumvoll, M. et al., "Metabolic Effects of Metformin in Non-Insulin-Dependent Diabetes Mellitus," 333(9) <i>The New England Journal of Medicine</i> 550-554 (1995).
C54	Suzuki, S et al., "Molecular Mechanism of Insulin Resistance in Spontaneous Diabetic GK (Goto-Kakizaki) Rats," In: <i>New Directions in Research and Clinical Works for Obesity and Diabetes Mellitus</i> , Eds. Sakamoto, N., Angel, A., Hotta, N., pp. 197-203. Elsevier (1991).
C55	Suzuki, S. et al., "Urinary-chiro-Inositol Excretion is an Index Marker of Insulin Sensitivity in Japanese Type II Diabetes," 17(12) <i>Diabetes Care</i> 1465-1468 (1994).
C56	United Kingdom Prospective Diabetes Study, "United Kingdom Prospective Diabetes Study (UKPDS) 13: Relative Efficacy of Randomly Allocated Diet, Sulphonylurea, Insulin or Metformin in Patients with Newly Diagnosed Non-Insulin Dependent Diabetes Followed for Three Years," 310 <i>BMJ</i> 83-88 (1995).
C57 ***	Varese, R.V. et al., "Insulin-induced Activation of Glycerol 3-Phosphate Acyltransferase by chiro-inositol-containing Insulin Mediator is Defective in Adipocytes of Insulin resistant, Type II Diabetic Goto-Kakizaki Rats," 91 <i>Proc. Natl. Acad. Sci.</i> 11040-11044 (1994).
C58	Villar-Palasi, C. and Farese, R., "Impaired Skeletal Muscle Glycogen Synthase Activation by Insulin in the Goto-Kakizaki (G/K) Rat," 37 <i>Diabetologia</i> 885-888 (1994).
C59	Walker, M., "Obesity, Insulin Resistance, and Its Link to Non-Insulin-Dependent Diabetes Mellitus," 44(9) (Suppl. 3) <i>Metabolism</i> 18-20 (1995).
C60	Williams, B., "Insulin Resistance: The Shape of Things to Come," 344 <i>The Lancet</i> 521-524 (1994).
C61	Williams, R. and Palmer, J., "Farewell to Phenformin for Treating Diabetes Mellitus," 83(4) <i>Annals of Internal Medicine</i> 567-568 (1975).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant(s).